Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain

M. Hassan; H. Ehrsson; I. Wallin; S. Eksborg

doi:10.1007/bf03190094

journal article Oct 01, 1988

Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain

M. Hassan H. Ehrsson I. Wallin S. Eksborg

European Journal of Drug Metabolism and Pharmacokinetics Vol. 13 No. 4 pp. 301-305 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf03190094

Topics

No keywords indexed for this article. Browse by subject →

References

19

[1]

Santos G.W., Tutschka P.J., Brookmeyer R., Saral R., Beschomer W.E., Bias W.B., et al. (1983): Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med., 309, 1347–1353. 10.1056/nejm198312013092202

[2]

Tutschka P.J., Copelan E.A., Klein J.P. (1987): Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood, 70, 1382–1388. 10.1182/blood.v70.5.1382.1382

[3]

Parkman R., Rappeport J.M., Hellman S., Lipton J., Smith B., Geha R., Nathan D.G. (1984): Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation. Blood, 64, 852–857. 10.1182/blood.v64.4.852.852

[4]

Stephani U., Rating D., Korinthenberg R., Siemes H., Riehm H., Hanefeld F. (1983): Radiation-related disturbance of blood/brain barrier during therapy of acute lymphoblastic leukemia. Lancet, II, 1036–1037. 10.1016/s0140-6736(83)91030-9

[5]

Deeg H.J., Sullivan K.M., Buckner C.D., Starb R., Appelbaum F.R., Clift R.A., Doney K., Sanders J.E., Witherspoon R.P., Thomas E.D. (1986): Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant., 1, 151–157.

[6]

Hobbs J.R., Hugh-Jones K., Shaw P.J., Downie C.J.C., Williamson S. (1986): Engraftment rates related to busulphan and cyclophosphamide dosage for displacement bone marrow transplants in fifty children. Bone Marrow Transplant., 1, 201–208.

[7]

Peng C-T. (1957): Distribution and metabolic fate of S35-labeledmyleran (busulfan) in normal and tumor-bearing rats. J. Pharmacol., 120, 229–238.

[8]

Trams E.G., Nadkami M.V., deQuattro V., Maengwyn-Davies G.D., Smith P.K. (1959): Dimethanesulphonoxybutane (myleran) preliminary studies on distribution arid metabolic fate in the rat. Biochem. Pharmacol., 2, 7–16. 10.1016/0006-2952(59)90052-8

[9]

Hassan M., Ehrsson H. (1986): Degradation of busulfan in aqueous solution. J. Pharm. Biomed. Anal., 4, 95–101. 10.1016/0731-7085(86)80027-9

[10]

Hassan M., Ehrsson H. (1987): Urinary metabolites of busulfanin the rat. Drug Metab. Dispos., 15, 399–402. 10.1016/s0090-9556(25)06715-7

[11]

Hassan M., Ehrsson H. (1983): Gas chromatographic detennination of busulfan in plasma with electron-capture detection. J. Chromatogr., 277, 374–380. 10.1016/s0378-4347(00)84861-6

[12]

Ehrnebo M., Agurell S., Boreus L.O., Gordon E., Lonroth U. (1974): Pentazocine binding to blood cells and plasma proteins. Clin. Pharmacol. Ther., 16, 424–429. 10.1002/cpt1974163part1424

[13]

Gjedde A. (1986): The selective barrier between blood and brain. Trends Biochem. Sci., 11, 525–527. 10.1016/0968-0004(86)90089-7

[14]

Hansh C., Björkroth J.P., Leo A. (1987): Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J. Pharm. Sci., 76, 663–687. 10.1002/jps.2600760902

[15]

Ehrsson H., Lönroth U. (1982): Degradation of melphalan in aqueous solution-influence of human albumin binding. J. Pharm. Sci., 71, 826–827. 10.1002/jps.2600710729

[16]

Ehrsson B., Lönroth U., Wallin I., Ehmebo M., Nilsson S.O. (1981): Degradation of chlorambucil in aqueous solution — influence of human albumin binding. J. Pharm. Pharmaeol., 33, 313–315. 10.1111/j.2042-7158.1981.tb13787.x

[17]

Greig N.H., Sweeney D.J., Rapoport S.I. (1988): Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemother. Pharmacol., 21, 1–8. 10.1007/bf00262729

[18]

Shapiro W.R., Young D.F., Mehta B.M. (1975): Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med., 293, 161–166. 10.1056/nejm197507242930402

[19]

Oldendorf W.H. (1983): Aspects of blood-brain barrier in clinical brain imaging. Acta Neuropathol. (Berl.) Suppl., VIII, 111–117.

Metrics

32

Citations

19

References

Details

Published: Oct 01, 1988
Vol/Issue: 13(4)
Pages: 301-305
License: View

Authors

Cite This Article

M. Hassan, H. Ehrsson, I. Wallin, et al. (1988). Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. European Journal of Drug Metabolism and Pharmacokinetics, 13(4), 301-305. https://doi.org/10.1007/bf03190094

Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain

You May Also Like